J&J's daratumumab extends survival in first-line multiple myeloma

• Genmab A/S (NASDAQ:GMAB) announces positive results from the second part of a Phase 3 clinical trial, CASSIOPEIA, evaluating daratumumab as maintenance treatment versus no treatment in newly diagnosed multiple myeloma (MM) patients who are eligible for autologous stem cell transplantation.
• Part 2, conducted by the French Intergroupe Francophone du Myelome in collaboration with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and and Janssen Research & Development, LLC, a unit of Johnson & Johnson (NYSE:JNJ), met the primary endpoint of progression-free survival at a pre-planned interim analysis with 47% less risk of cancer progression or death (hazard ratio = 0.53).
• The independent Data Monitoring Committee has recommended unblinding the data.
• Licensee Janssen Biotech plans to discuss the submission of marketing applications for the indication with health authorities.
• Daratumumab, marketed by Janssen under the brand name Darzalex, was first approved in the U.S. in November 2015 for previously treated MM patients.
• https://seekingalpha.com/news/3624549-j-and-js-daratumumab-extends-survival-in-first-line-multiple-myeloma